New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment

• Published in: Drugs in R&D Vol. 18; no. 3; pp. 237 - 245
• Main Authors: Tellone, Valeria, Coppola, Paola, Ammendola, Marco, Di Loreto, Giorgio, Picollo, Rossella, Del Vecchio, Alessandra, Comandini, Alessandro, Garofolo, Fabio, Tongiani, Serena
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2018; Springer Nature B.V
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacokinetics; Dioxolanes - administration & dosage; Dioxolanes - pharmacokinetics; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluoroquinolones - administration & dosage; Fluoroquinolones - analysis; Fluoroquinolones - pharmacokinetics; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Piperazines - administration & dosage; Piperazines - analysis; Piperazines - pharmacokinetics; Renal Insufficiency - drug therapy; Urine; Young Adult

Background The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. Objective We aimed to provide new insights on the pharmacokinetics (PK) of u...